NEW YORK (GenomeWeb) – Paradigm today announced a collaboration with Deciphera Pharmaceuticals to predict best responders for Deciphera's kinase inhibitor called altiratinib. 

Paradigm will use its PCDx panel to characterize patient tissue samples in a phase I clinical study of altiratinib in order to determine which patients may be sensitive or resistant to the MET, TIE2, VEGFR2, and TRK (A,B,C) kinase inhibitor. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A genome-wide association study highlights a potential role for hair follicles in acne risk, according to New Scientist.

Newsday reports that breast cancer genetic testing guidelines for are out of date and may miss individuals.

In Cell this week: gene editing-based strategy to screen for immune system regulators, ancient plague patterns, and more.

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.